Bioassays on FO probe surface. The surface of the gold-coated fiber-optic probe has a carboxyl monolayer to which capture antibodies are covalently bound. Target antibodies bind the capture antibodies in a label-free configuration (left). Alternatively, the signal can be enhanced by using gold nanoparticles functionalized with detection antibodies in a sandwich assay configuration (right) extending detection to the pM and fM range.
The FOx BIOSYSTEMS biosensor can accurately detect, quantify and measure the potency of your antibody of interest in a variety of sample matrices. Label-free pM to µM sensitivities in 10 minutes make our fiber-optic surface plasmon resonance (FO-SPR) biosensor a versatile development tool.
- Fast assay time (10 min)
- Clinically relevant sensitivity is in reach of either label-free or fast labeled amplification assays
- Results better than ELISA, in much less time
- Minimum sample preparation (serum, plasma and whole blood)
Therapeutic drug monitoring
Infliximab (IFX) is a monoclonal antibody used for the treatment of inflammatory bowel disease. Optimizing the therapeutic outcome requires concentration measurements which are currently obtained using the slow ELISA or less sensitive lateral flow-based immunotherapy techniques.
Immediate dose adaptation is a challenge using these techniques because they require well-trained staff, a long time to result, and sample prep on serum samples.
FOx BIOSYSTEMS offers an accurate, fast and convenient alternative to currently used techniques. This study showed that the FO-SPR biosensor provided excellent agreement with ELISA, even for serum and plasma samples.
Antibody concentrations obtained with
FO-SPR correlate with those obtained with ELISA
Label-free potency screening of antibody–antigen interaction: FO-SPR can reproducibly measure and rank potency across a library.
Quick, label-free quantification of antibodies reveals no information about their functionality, since they could be denatured but still detected. By adding a second step to bind the target of the antibody, the signal relative to the amount of antibody present is a strong indication of its performance. This allows fast and sensitive measurement and ranking of the antigen-binding potency of a set of antibodies.
Page 1 of 1
Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn’s disease
January 29, 2024
November 20, 2023
February 15, 2023
Innovative FO-SPR Label-free Strategy for Detecting Anti-RBD Antibodies in COVID-19 Patient Serum and Whole Blood
January 27, 2022
August 24, 2021
White paper: WP3 Sensitive protein quantification in whole blood, dried blood spots, serum and plasma
June 29, 2021
April 23, 2021
Immunoassay for detection of infliximab in whole blood using a fiber-optic surface plasmon resonance biosensor
February 22, 2017
Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients
May 15, 2016
February 20, 2014
Selection of aptamers against Ara h 1 protein for FO-SPR biosensing of peanut allergens in food matrices
May 15, 2013
February 15, 2011
Page 1 of 1
For Research Use Only. Not for use in diagnostic procedures.